In partnership with
AIHealthTech Insider: Issue #96
April 13, 2026
This issue covers AI outperforming surgeons in liver surgery assessment, a handheld retinal camera cleared by the FDA, Fitbit pulling in medical records, gaps in pediatric AI devices, and a cheap statin that may improve CAR-T outcomes.
Summaries are for education, not medical advice. Always verify locally before clinical use.
🔬 The Big Story
An AI watched liver surgery — and outperformed the surgeons doing it
A new study in Scientific Reports just showed something quietly remarkable: an AI watching liver surgery videos read the liver more accurately than the surgeons holding the instruments.
Here's why that matters. When surgeons remove a tumor from a liver, they have to judge by eye how scarred the rest of the organ is. Get it wrong, and the patient may lose too much liver, or recover badly. It's one of the trickiest calls in the OR.
Image source: ChatGPT/AIHealthTech Insider
Researchers fed surgery footage from 103 cancer patients into a deep learning model and asked it to make the same call. The results:
AI: 92.7% accurate
Experienced surgeons: 84.4%
Less experienced surgeons: 80.8%
The AI also beat the standard blood tests doctors use before surgery (APRI, FIB-4)
In plain terms: a machine watching the same liver, in real time, beat five experienced surgeons. If this holds up in bigger trials, every minimally invasive liver OR could soon have a quiet second pair of eyes.
Note: the paper is an accepted manuscript awaiting final editing; the findings are early but peer-reviewed.
Sponsored
The ones showing up in LLMs convert 3× better than Google
They optimized for LLMs, not just Google.
FAQs. Comparison pages. Transparent pricing. LinkedIn presence. These aren't vanity plays. They're what gets you cited in ChatGPT, Gemini, and Claude when your buyers are researching, your investors are looking, and your future hires are deciding where to work.
Download the free AEO Playbook for Startups from HubSpot and get the exact checklist. Five minutes to read.
⚡ Quick Hits
Image source: ChatGPT/AIHealthTech Insider
🔸A pocket-sized AI retinal camera just cleared the FDA
AI Optics' Sentinel Camera, a handheld retinal imaging system, received FDA clearance. It captures images without eye dilation, reducing specialist visits. The company is partnering with NYU Langone Health to offer screenings for eye conditions in primary care clinics.
👉 Source → https://www.modernretina.com/view/ai-optics-portable-sentinel-camera-gains-fda-510-k-clearance
🔸Your Fitbit just became your medical records hub
Google and CMS partnered to let patients securely access medical records in the Fitbit app, reducing provider fragmentation. Starting in April, Fitbit users can connect a continuous glucose monitor via Health Connect and use the AI coach to track glucose level impacts. The Google wristband is becoming a personal health command center.
👉 Source → https://blog.google/innovation-and-ai/technology/health/google-check-up-health-ai-updates-2026/
🔸30 years of AI medical devices — and almost none are made for kids
A JAMA Network Open study found that out of 952 AI-enabled medical devices cleared by the FDA from 1995 to 2024, only 42 were labeled for children, with just 5 exclusively for pediatric use. Pediatric devices faced longer FDA review times, highlighting that children are often overlooked in the AI healthcare boom due to limited datasets and challenging trials.
🔸AI caught lung cancer misdiagnoses in 3% of cases — and changed treatment plans
A JAMA Network Open study by Caris Life Sciences revealed that an AI model misdiagnosed 3.1% of nearly 4,000 lung squamous cell carcinoma cases as metastatic cancers, potentially leading to incorrect treatments for thousands of patients each year.
Sponsored
Your AI is resolving tickets. Is it keeping customers?
Resolution rates look great. But Gladly's 2026 Customer Expectations Report reveals the metric most CIOs are missing — and what the data says about where AI investments actually translate into retention, not just throughput.
🌍 Beyond AI
A $4 cholesterol pill may quietly supercharge a $400,000 cancer therapy
This one isn’t about AI. But it’s too important to ignore.
A new study in Blood Immunology & Cellular Therapy found something surprising: lymphoma patients getting CAR-T cell therapy did dramatically better if they happened to already be taking statins — the same cheap generic pills millions take for cholesterol.
Image source: ChatGPT/AIHealthTech Insider
The numbers from 84 patients with relapsed large B-cell lymphoma:
Statin users: median survival not yet reached
Non-users: about 17 months
Deaths at last follow-up: 22% (statin) vs 42% (non-statin)
The two scariest CAR-T side effects — severe inflammation and brain toxicity — were also lower in statin users
Why might this work? Statins quietly calm inflammation and may stop immune cells from "burning out" the main reason CAR-T sometimes fails.
It's early days, and bigger trials are needed before anyone changes practice. But the idea that a $4-a-month pill could boost the success of a $400,000 cancer therapy is exactly the kind of finding that gets oncologists' attention.
Sponsored
Are you tracking agent views on your docs?
AI agents already outnumber human visitors to your docs — now you can track them.
💡 The One Thing
AI is no longer the future of medicine — it's the present. It's in ORs, pathology labs, and primary care clinics, often outperforming the humans next to it. But this issue is a reminder that the cutting edge isn't always what wins. Sometimes it's a $4 pill. Sometimes it's better access for kids. Smarter machines matter less than who gets to benefit from them.
Image source: ChatGPT/AIHealthTech Insider
Would you let an AI second-guess your surgeon mid-operation?
Stay ahead: AI Healthcare News!
This is just a glimpse of the AI healthcare revolution. Subscribe for exclusive updates on medicine’s future!
